xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06018935</url>
    </required_header>
    <id_info>
      <org_study_id>LCATM202304</org_study_id>
      <nct_id>NCT06018935</nct_id>
    </id_info>
    <brief_title>A Cohort Establishment Study of Total Management of Ovarian Cancer</brief_title>
    <official_title>A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Sichuan Cancer Hospital and Research Institute</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Sichuan Cancer Hospital and Research Institute</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        A cohort establishment study of total management of ovarian cancer (including fallopian tube&#xD;
        cancer and primary peritoneal cancer).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related&#xD;
             factors on the prognosis and quality of life of patients with ovarian cancer (including&#xD;
             fallopian tube cancer and primary peritoneal cancer);&#xD;
  &#xD;
          2. To study the postoperative recovery of patients with ovarian cancer (including fallopian&#xD;
             tube cancer and primary peritoneal cancer), perioperative complications, adverse&#xD;
             reactions after chemotherapy, adverse reactions during targeted drug maintenance&#xD;
             therapy, and explore possible effective preventive measures;&#xD;
  &#xD;
          3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary&#xD;
             peritoneal cancer) were analyzed;&#xD;
  &#xD;
          4. To study the efficacy and safety of PARPi in clinical application in patients with&#xD;
             ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 10, 2023</start_date>
    <completion_date type="Anticipated">September 1, 2025</completion_date>
    <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Progress Freesurvival (PFS)</measure>
      <time_frame>Average six months after study completion.</time_frame>
      <description>The time from the start of treatment until the patient progresses further or dies.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Overall Survival (OS)</measure>
      <time_frame>Average six months after study completion.</time_frame>
      <description>Measure the time from the start of treatment to the time of death.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Occurrence of adverse reactions</measure>
      <time_frame>Average six months after study completion.</time_frame>
      <description>All adverse events were recorded.</description>
    </secondary_outcome>
    <enrollment type="Anticipated">500</enrollment>
    <condition>Tumor of Female Reproductive System</condition>
    <condition>Ovarian Cancer</condition>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>No intervention</intervention_name>
      <description>No intervention</description>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal&#xD;
          cancer) and intended to be treated in our hospital&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary&#xD;
               peritoneal cancer) and intended to be treated in our hospital;&#xD;
  &#xD;
            2. Can cooperate with later follow-up.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Patients with other malignant tumors or previous history of other malignant tumors;&#xD;
  &#xD;
            2. Have cognitive impairment.&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Dengfeng Wang, Learned scholar</last_name>
      <phone>15982222707</phone>
      <email>wonderful_96@163.com</email>
    </overall_contact>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 10, 2023</study_first_submitted>
    <study_first_submitted_qc>August 30, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 31, 2023</study_first_posted>
    <last_update_submitted>September 13, 2023</last_update_submitted>
    <last_update_submitted_qc>September 13, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
      <investigator_full_name>Dengfeng Wang</investigator_full_name>
      <investigator_title>Deputy chief</investigator_title>
    </responsible_party>
    <keyword>Ovarian cancer</keyword>
    <keyword>Cohort study</keyword>
    <keyword>Whole-process management</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Ovarian Neoplasms</mesh_term>
      <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
      <mesh_term>Genital Neoplasms, Female</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06018935
  org study id: LCATM202304
  nct id: NCT06018935
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  A cohort establishment study of total management of ovarian cancer (including fallopian tube
        cancer and primary peritoneal cancer).
  1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related
             factors on the prognosis and quality of life of patients with ovarian cancer (including
             fallopian tube cancer and primary peritoneal cancer);
  
          2. To study the postoperative recovery of patients with ovarian cancer (including fallopian
             tube cancer and primary peritoneal cancer), perioperative complications, adverse
             reactions after chemotherapy, adverse reactions during targeted drug maintenance
             therapy, and explore possible effective preventive measures;
  
          3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary
             peritoneal cancer) were analyzed;
  
          4. To study the efficacy and safety of PARPi in clinical application in patients with
             ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
  observational model: Cohort
  time perspective: Prospective
  measure: Progress Freesurvival (PFS)
  time frame: Average six months after study completion.
  description: The time from the start of treatment until the patient progresses further or dies.
  measure: Overall Survival (OS)
  time frame: Average six months after study completion.
  description: Measure the time from the start of treatment to the time of death.
  measure: Occurrence of adverse reactions
  time frame: Average six months after study completion.
  description: All adverse events were recorded.
  intervention type: Other
  intervention name: No intervention
  description: No intervention
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: Female
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: Dengfeng Wang, Learned scholar
  phone: 15982222707
  email: wonderful_96@163.com
  responsible party type: Principal Investigator
  investigator affiliation: Sichuan Cancer Hospital and Research Institute
  investigator full name: Dengfeng Wang
  investigator title: Deputy chief
  mesh term: Ovarian Neoplasms
  mesh term: Carcinoma, Ovarian Epithelial
  mesh term: Genital Neoplasms, Female
  sharing ipd: No